Citrus Bergamot Supplement Endothelial Function Randomized Trial: What the Evidence Says

Quick Answer

Citrus Bergamot Supplement Endothelial Function Randomized Trial has 1 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 research article.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Nutrients Advances in Nutrition for MASLD Management: Current Perspectives from the Bench to the Bedside Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), has emerged as the most prevalent chronic liver disease worldwide, with an overall global prevalence of 30%. [Rodriguez-Ramiro Ildefonso (2026); evidence level 4]
• It encompasses from hepatic steatosis, through to metabolic dysfunction-associated steatohepatitis (MASH), the progressive necroinflammatory disease form that can progress to fibrosis, cirrhosis, and hepatocellular carcinoma. [Rodriguez-Ramiro Ildefonso (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For citrus bergamot supplement endothelial function randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Rodriguez-Ramiro Ildefonso (2026). Advances in Nutrition for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Current Perspectives from the Bench to the Bedside. DOI: 10.3390/nu18111708. PMCID: PMC13258139. PMID: 42280351. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13258139/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.